DexCom Price Target Raised by Morgan Stanley to $89.00, Maintains Equal-Weight Rating

Tuesday, Jul 15, 2025 9:09 pm ET1min read

Morgan Stanley has raised its price target for DexCom (DXCM) to $89.00, an 8.54% increase from the previous target of $82.00. The analyst maintains an "Equal-Weight" rating for the stock, indicating a neutral stance on its expected performance. The average target price for DXCM is $99.82, with an upside of 16.98% from the current price of $85.33.

Morgan Stanley has updated its price target for DexCom (DXCM), one of the leaders in glucose monitoring technology. The new price target set by analyst Patrick Wood is $89.00, up from the previous target of $82.00. This revision marks an 8.54% increase from the prior target, reflecting a more optimistic view on the future performance of DexCom. Despite the increase in the price target, Morgan Stanley maintains its "Equal-Weight" rating for (DXCM), indicating a neutral stance on the stock's expected performance relative to the broader market [1].

The update was released on July 15, 2025, and has caught the attention of investors monitoring DexCom within the healthcare sector. The adjustment suggests Morgan Stanley's acknowledgment of improving metrics or growth potential within DexCom's operations, warranting the raised price outlook.

Wall Street Analysts Forecast
Based on the one-year price targets offered by 26 analysts, the average target price for DexCom Inc (DXCM) is $99.82 with a high estimate of $115.00 and a low estimate of $82.00. The average target implies an upside of 16.98% from the current price of $85.33 [1].

Based on the consensus recommendation from 28 brokerage firms, DexCom Inc's (DXCM) average brokerage recommendation is currently 1.7, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell [1].

Based on GuruFocus estimates, the estimated GF Value for DexCom Inc (DXCM) in one year is $169.00, suggesting an upside of 98.05% from the current price of $85.33. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance [1].

References
[1] https://www.gurufocus.com/news/2978108/dexcom-dxcm-price-target-raised-by-morgan-stanley-dxcm-stock-news

DexCom Price Target Raised by Morgan Stanley to $89.00, Maintains Equal-Weight Rating

Sign up for free to continue reading

Unlimited access to AInvest.com and the AInvest app
Follow and interact with analysts and investors
Receive subscriber-only content and newsletters

By continuing, I agree to the
Market Data Terms of Service and Privacy Statement

Already have an account?
Aime Insights

Aime Insights

How might the AI Gold Rush affect the overall market trend?

What factors contributed to Reddit's significant earnings growth?

How does AI technology influence Western Digital's stock performance?

What is the current market sentiment towards tech and AI stocks?